Literature DB >> 13304350

Myleran in treatment of chronic myeloid leukaemia.

E K BLACKBURN, G M KING, H T SWAN.   

Abstract

Entities:  

Keywords:  GLYCOLS/therapeutic use; LEUKEMIA, MYELOCYTIC/therapy

Mesh：

Substances：

Year:  1956        PMID： 13304350      PMCID： PMC1979505          DOI： 10.1136/bmj.1.4971.835

Source DB:  PubMed          Journal:  Br Med J        ISSN： 0007-1447


× No keyword cloud information.
  5 in total

1.  Myleran (GT 41) in the treatment of leukaemia.

Authors:  A VIDEBAEK
Journal:  Acta Med Scand       Date:  1955-04-16

2.  Myleran in chronic myeloid leukaemia; results of treatment.

Authors:  D A GALTON
Journal:  Lancet       Date:  1953-01-31       Impact factor: 79.321

3.  Myleran in chronic myeloid leukaemia; chemical constitution and biological action.

Authors:  A HADDOW; G M TIMMIS
Journal:  Lancet       Date:  1953-01-31       Impact factor: 79.321

4.  Myelocytic leukemia: an analysis of incidence, distribution and fatality, 1910-1948.

Authors:  M B SHIMKIN; S R METTIER; H R BIERMAN
Journal:  Ann Intern Med       Date:  1951-07       Impact factor: 25.391

5.  The effect of 1,4-dimethanesulfonyloxybutane (GT-41 or myleran) upon leukemia.

Authors:  N L PETRAKIS; H R BIERMAN; K H KELLY; L P WHITE; M B SHIMKIN
Journal:  Cancer       Date:  1954-03       Impact factor: 6.860
  5 in total
  6 in total

1.  The chemotherapy of malignant disease.

Authors:  R B SCOTT
Journal:  Br Med J       Date:  1958-01-04

2.  Medullary aplasia in chronic myeloid leukaemia during busulphan therapy.

Authors:  F G HAYHOE; D KOK
Journal:  Br Med J       Date:  1957-12-21

3.  Treatment of chronic myeloid leukaemia with mercaptopurine.

Authors:  J R FOUNTAIN
Journal:  Br Med J       Date:  1956-12-08

4.  Residual effects of busulfan and irradiation on murine hematopoietic stem and progenitor cells.

Authors:  Kaylind Batey; Jisoo Kim; Lauren Brinster; Gladys Gonzalez-Matias; Zhijie Wu; Sabrina Solorzano; Jichun Chen; Xingmin Feng; Neal S Young
Journal:  Exp Hematol       Date:  2021-11-08       Impact factor: 3.084

5.  Preclinical IV busulfan dose-finding study to induce reversible myeloablation in a non-human primate model.

Authors:  Nadim Mahmud; Amit Khanal; Simona Taioli; Emre Koca; Sujata Gaitonde; Benjamin Petro; Karen Sweiss; Lisa Halliday; Xinhe Wang; Pritesh Patel; Damiano Rondelli
Journal:  PLoS One       Date:  2018-11-29       Impact factor: 3.240

6.  Busulphan in the treatment of chronic granulocytic leukaemia.

Authors:  J M BRIDGES; D M HAYES; M G NELSON
Journal:  Br J Cancer       Date:  1961-09       Impact factor: 7.640
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.